{"log_id": 840922658397123401, "direction": 3, "words_result_num": 30, "words_result": [{"probability": {"variance": 0, "average": 0.967413, "min": 0.967413}, "location": {"width": 31, "top": 299, "height": 34, "left": 1994}, "words": "古"}, {"probability": {"variance": 0.014527, "average": 0.910862, "min": 0.57547}, "location": {"width": 38, "top": 388, "height": 872, "left": 1930}, "words": "(2)挣脉滴注135mgm2,衡注时间大干24小时,j给子75mpm"}, {"probability": {"variance": 0.01523, "average": 0.924245, "min": 0.42842}, "location": {"width": 36, "top": 379, "height": 934, "left": 1873}, "words": "左于已经接受过化疗的卵巢患者,且前剂量和力案仁儿种,但最佳的剂"}, {"probability": {"variance": 0.030198, "average": 0.883928, "min": 0.433421}, "location": {"width": 38, "top": 299, "height": 1012, "left": 1816}, "words": "方案还不清楚,荐治疗方案为:静滴注135mg/m2成共175mg/m2,每周"}, {"probability": {"variance": 0.02815, "average": 0.825442, "min": 0.460373}, "location": {"width": 34, "top": 299, "height": 342, "left": 1764}, "words": "箔泣1次,时间大于3小时"}, {"probability": {"variance": 0.013516, "average": 0.951483, "min": 0.587076}, "location": {"width": 38, "top": 354, "height": 445, "left": 1702}, "words": "对乳腺志,荐使用下列法"}, {"probability": {"variance": 0.029228, "average": 0.892959, "min": 0.378273}, "location": {"width": 36, "top": 377, "height": 932, "left": 1645}, "words": "对温巴结阳长的乳腺的辅力治疗方案是:剂最为175gm2静脉滴注"}, {"probability": {"variance": 0.031463, "average": 0.896154, "min": 0.370517}, "location": {"width": 63, "top": 294, "height": 1085, "left": 1567}, "words": "大于3小时,每3周1次,4个疗程,在今阿霉的联合化疗后序贯使用临"}, {"probability": {"variance": 0.002687, "average": 0.962796, "min": 0.832756}, "location": {"width": 36, "top": 294, "height": 612, "left": 1533}, "words": "研究中用的是阿再素联合环配胺化疗4个疗行"}, {"probability": {"variance": 0.024467, "average": 0.918328, "min": 0.364402}, "location": {"width": 68, "top": 347, "height": 1115, "left": 1455}, "words": "2对初化疗尖败的转移性疾病或者辅化疗6个月丙出现复白有"}, {"probability": {"variance": 0.032777, "average": 0.874963, "min": 0.363044}, "location": {"width": 34, "top": 297, "height": 788, "left": 1421}, "words": "效泞疗方案为:175my/m3,静脉超过了小时注,每31次"}, {"probability": {"variance": 0.017369, "average": 0.92674, "min": 0.598891}, "location": {"width": 36, "top": 351, "height": 411, "left": 1364}, "words": "对非小细胞肺癌患名推荐方案为"}, {"probability": {"variance": 0.029693, "average": 0.878539, "min": 0.480269}, "location": {"width": 34, "top": 374, "height": 710, "left": 1307}, "words": "5mg/m2,静脉滴注,注时间大于3小时。每3周1次"}, {"probability": {"variance": 0.01927, "average": 0.920139, "min": 0.452116}, "location": {"width": 41, "top": 349, "height": 616, "left": 1247}, "words": "对艾滋病相关性卡波氏肉瘤,推荐的治疗方室为"}, {"probability": {"variance": 0.031749, "average": 0.867347, "min": 0.363834}, "location": {"width": 38, "top": 365, "height": 916, "left": 1190}, "words": "35mg/m2,静肽液注,注时间大下3小时,何31次或者1C0mg/m"}, {"probability": {"variance": 0.017564, "average": 0.918614, "min": 0.372286}, "location": {"width": 36, "top": 292, "height": 982, "left": 1138}, "words": "静脉滴江,滴江时间太于3小时剂量强度为45-50mim2wek),每21次"}, {"probability": {"variance": 0.02802, "average": 0.892467, "min": 0.390186}, "location": {"width": 36, "top": 292, "height": 1014, "left": 1080}, "words": "车临床究中,每3周1次静脉给予13mg/m3,滴注时间于3小时的卉性比"}, {"probability": {"variance": 0.026954, "average": 0.892697, "min": 0.444979}, "location": {"width": 41, "top": 292, "height": 1010, "left": 1019}, "words": "后者更大。另外,所有体能状态较苯的患者,使用了后方案(母两周静脉给予"}, {"probability": {"variance": 0.030159, "average": 0.87277, "min": 0.411246}, "location": {"width": 36, "top": 306, "height": 399, "left": 966}, "words": "0g/m2,注时间大于3小时"}, {"probability": {"variance": 0.026678, "average": 0.894583, "min": 0.37704}, "location": {"width": 38, "top": 349, "height": 891, "left": 907}, "words": "鉴于进展的HIV患者均在免疫抑制,对这些患考荐使用改良方案"}, {"probability": {"variance": 0.025339, "average": 0.886765, "min": 0.458924}, "location": {"width": 38, "top": 345, "height": 952, "left": 847}, "words": "1.减少二种顶用药中的地松的剂,用三为口服1Og而个是20mg)"}, {"probability": {"variance": 0.027403, "average": 0.8858, "min": 0.396869}, "location": {"width": 34, "top": 342, "height": 962, "left": 797}, "words": "2只与当中性粒红胞数少为00个mm3时;才可首次或名再次使用本"}, {"probability": {"variance": 0.015094, "average": 0.850995, "min": 0.683488}, "location": {"width": 31, "top": 290, "height": 95, "left": 742}, "words": "nh治疗:"}, {"probability": {"variance": 0.028749, "average": 0.875306, "min": 0.403882}, "location": {"width": 41, "top": 345, "height": 948, "left": 678}, "words": "3.对严重中性拉细胞减症(粒细胞小500个mm3持续一周或更长"}, {"probability": {"variance": 0.014456, "average": 0.92391, "min": 0.524974}, "location": {"width": 36, "top": 287, "height": 626, "left": 623}, "words": "的患者,在后血疗程中紫的剂量减少2U%"}, {"probability": {"variance": 0.015479, "average": 0.901461, "min": 0.563278}, "location": {"width": 34, "top": 345, "height": 315, "left": 569}, "words": "4.临床需要使用-CST"}, {"probability": {"variance": 0.021555, "average": 0.92231, "min": 0.376034}, "location": {"width": 38, "top": 342, "height": 959, "left": 509}, "words": "对实体瘤的治疗(卵巢、乳腺和非小细胞肺癌),只有当中性粒红电至"}, {"probability": {"variance": 0.007306, "average": 0.948587, "min": 0.643724}, "location": {"width": 41, "top": 285, "height": 1014, "left": 452}, "words": "少为150个mm3,血小板至少为10,0个/mm3时,才可再次使用本品。对于"}, {"probability": {"variance": 0.021234, "average": 0.891291, "min": 0.512324}, "location": {"width": 38, "top": 303, "height": 998, "left": 397}, "words": "线或后续的中性粒细抱数低于100个mm3的A0相关性卡波长内瘤者不"}, {"probability": {"variance": 0.006576, "average": 0.960727, "min": 0.65426}, "location": {"width": 36, "top": 290, "height": 1007, "left": 340}, "words": "能使用本品。在本品治疗过程中出现了“重的中性粒细减少症(中性粒细胞小"}], "language": 3}